8-K: Brainstorm Cell Therapeutics Implements 1-for-15 Reverse Stock Split to Maintain Nasdaq Listing

Brainstorm Cell Therapeutics enacted a 1-for-15 reverse stock split on September 30, 2024, to boost its share price and meet Nasdaq's minimum bid price requirement.

Summary

• Brainstorm Cell Therapeutics implemented a reverse stock split at a ratio of one-for-fifteen on September 30, 2024.
• The reverse stock split was enacted to increase the company's stock price to meet Nasdaq's minimum bid price requirement of $1.00.
• The reverse stock split became effective at 11:59 p.m. Eastern Time on September 30, 2024.
• Every fifteen shares of common stock were combined into one share.
• No fractional shares were issued; instead, shareholders received cash equal to the fractional share's value based on the closing price on the last trading day before the split.
• Trading on a split-adjusted basis commenced on October 1, 2024.
• The new CUSIP number for the common stock is 10501E 300.
• The number of authorized shares remains at 250 million.
• The reverse stock split also applies to outstanding warrants, stock options, and restricted stock units, with proportionate adjustments to their exercise prices.

Sentiment

Score: 5

Explanation: The document describes a necessary but potentially negative action (reverse stock split) to maintain listing compliance. While the company is taking steps to address the issue, the underlying reason for the split is concerning.

Positives

• The reverse stock split is intended to help the company maintain its listing on the Nasdaq by increasing the per share bid price above $1.00.
• The company is taking proactive steps to address compliance with Nasdaq listing standards.

Negatives

• The reverse stock split reduces the number of outstanding shares, which can be perceived negatively by some investors.
• The need for a reverse stock split indicates that the company's stock price was below the Nasdaq minimum bid price requirement.

Risks

• There is no guarantee that the reverse stock split will be sufficient to maintain the company's Nasdaq listing.
• The company's stock price may continue to fluctuate, and there is a risk that it could fall below the minimum bid price again.
• The reverse stock split could negatively impact investor sentiment.

Future Outlook

The company expects that the reverse stock split will increase the per share bid price of its common stock above the $1.00 required by Nasdaq's Minimum Bid Price Requirement.

Management Comments

• The company believes that effecting the Reverse Stock Split will assist in its efforts to meet the Nasdaq continued listing standards and to continue to have its common stock remain listed and traded on Nasdaq.

Industry Context

Reverse stock splits are a common action for companies facing delisting from major exchanges due to low share prices. This action is not unique to Brainstorm Cell Therapeutics and is often a measure to regain compliance with listing requirements.

Comparison to Industry Standards

• Many companies facing similar listing challenges have implemented reverse stock splits, such as Cassava Sciences (SAVA) which did a 1-for-5 split in 2020, and Ocugen (OCGN) which did a 1-for-10 split in 2023.
• The 1-for-15 ratio is relatively high compared to some other reverse stock splits, indicating a significant drop in the share price prior to the action.
• The success of this action will be measured by whether the company can maintain a share price above $1.00 for a sustained period, similar to how other companies are evaluated after a reverse split.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain relatively the same immediately after the split.
• Shareholders who held fractional shares received cash payments.
• The company's ability to remain listed on Nasdaq is important for investor confidence.

Next Steps

• The company will continue to trade on Nasdaq on a split-adjusted basis.
• The company will monitor its stock price to ensure continued compliance with Nasdaq listing requirements.

Key Dates

Keywords

reverse stock split, Nasdaq, minimum bid price, stock listing, common stock, share price, corporate action